In the current issue of JAMA Ophthalmology, Hogg and colleagues1 present the results of the Monitoring for Neovascular Age-Related Macular Degeneration Reactivation at Home (MONARCH) study, which examines the diagnostic accuracy of 3 different home-monitoring tests for detecting active neovascular age-related macular degeneration (nAMD) in patients who have received at least 6 months of treatment in 1 eye. As the retina community continues to improve our treatment strategies for nAMD, we are also increasing the treatment burden on patients, their families, and treating physicians.2